Advertisement
IRD vs IVF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRD is a Hold and IVF is a Buy.
IRD in +1.20% Uptrend, rising for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IRD's RSI Indicator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IRD as a result. In 89 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.498). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IVF in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
IVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 39 cases where IVF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVF's RSI Oscillator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on IVF as a result. In 69 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for IVF just turned positive on November 04, 2026. Looking at past instances where IVF's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +16.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in 157 of 190 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.333) is normal, around the industry mean (4.142). P/E Ratio (0.001) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.130) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IRD | IVF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 45 | 89 | |
P/E GROWTH RATING 1..100 | 84 | 97 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRD's Valuation (5) in the null industry is somewhat better than the same rating for IVF (40). This means that IRD’s stock grew somewhat faster than IVF’s over the last 12 months.
IRD's Profit vs Risk Rating (100) in the null industry is in the same range as IVF (100). This means that IRD’s stock grew similarly to IVF’s over the last 12 months.
IRD's SMR Rating (100) in the null industry is in the same range as IVF (100). This means that IRD’s stock grew similarly to IVF’s over the last 12 months.
IRD's Price Growth Rating (45) in the null industry is somewhat better than the same rating for IVF (89). This means that IRD’s stock grew somewhat faster than IVF’s over the last 12 months.
IRD's P/E Growth Rating (84) in the null industry is in the same range as IVF (97). This means that IRD’s stock grew similarly to IVF’s over the last 12 months.
| IRD | IVF | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 69% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| Declines ODDS (%) | 17 days ago 82% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IRD’s FA Score shows that 1 FA rating(s) are green while IVF’s FA Score has 0 green FA rating(s).
- IRD’s FA Score: 1 green, 4 red.
- IVF’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IRD’s TA Score shows that 5 TA indicator(s) are bullish while IVF’s TA Score has 5 bullish TA indicator(s).
- IRD’s TA Score: 5 bullish, 5 bearish.
- IVF’s TA Score: 5 bullish, 3 bearish.
Price Growth
IRD (@Biotechnology) experienced а +7.63% price change this week, while IVF (@Medical/Nursing Services) price change was +28.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
IRD is expected to report earnings on Nov 11, 2026.
IVF is expected to report earnings on Nov 16, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
IRD and
Correlation & Price change
A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
|---|---|---|---|---|
| IRD | 100% | +0.71% | ||
| ARRY - IRD | 35% Loosely correlated | -8.86% | ||
| PRME - IRD | 34% Loosely correlated | -9.30% | ||
| DMAC - IRD | 34% Loosely correlated | +0.21% | ||
| FDMT - IRD | 33% Poorly correlated | -0.16% | ||
| SRPT - IRD | 32% Poorly correlated | -4.76% | ||
More | ||||
IVF and
Correlation & Price change
A.I.dvisor indicates that over the last year, IVF has been loosely correlated with VNDA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IVF jumps, then VNDA could also see price increases.
| Ticker / NAME | Correlation To IVF | 1D Price Change % | ||
|---|---|---|---|---|
| IVF | 100% | +6.38% | ||
| VNDA - IVF | 40% Loosely correlated | -0.24% | ||
| IVA - IVF | 30% Poorly correlated | +2.86% | ||
| RANI - IVF | 30% Poorly correlated | -2.47% | ||
| IRD - IVF | 27% Poorly correlated | +0.71% | ||
| KPTI - IVF | 26% Poorly correlated | -56.50% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VTEB | 49.09 | -0.20 | -0.41% |
| Vanguard Tax-Exempt Bond ETF (VTEB) | |||
| KROP | 34.66 | -0.16 | -0.45% |
| Global X AgTech & Food Innovation ETF (KROP) | |||
| UEVM | 56.01 | -0.28 | -0.50% |
| VictoryShares Emerging Markets Value Momentum ETF (UEVM) | |||
| HLAL | 69.34 | -0.60 | -0.86% |
| Wahed FTSE USA Shariah ETF (HLAL) | |||
| PVEX | 29.91 | -0.29 | -0.96% |
| TrueShares ConVex Protect ETF (PVEX) | |||